A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)

Part of paid clinical trials in Dallas, Texas.

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT06284564
Phase
PHASE2
Status
Active Not Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

To learn if evolocumab and nivolumab can control metastatic and refractory renal cell carcinoma. The safety of this drug combination will also be studied.

Key Dates

Start date
Aug 7, 2024
Status verified
Apr 2026
Primary completion
Oct 1, 2026
Completion
Oct 1, 2026

Study Design

Enrollment
10 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Evolocumab + Nivolumab
    If you are found to be eligible to take part in this study, you will receive evolocumab and nivolumab on Day 1 of each cycle (every 4 weeks). Evolocumab will be given as an injection under the skin. Nivolumab will be given by vein over about 60 minutes.

Primary Outcome Measure

Safety and adverse events (AEs) [ Time Frame: Through study completion; an average of 1 year ]

Locations (2)

FacilityCityStateZIPSite coordinators
UT Southwestern Medical CenterDallasTexas75390-
MD Anderson Cancer CenterHoustonTexas77030-

Find similar trials in Dallas, TX

By condition
Kidney cancer
By specialty
OncologyUrology
By research site
UT Southwestern Medical Center· Dallas, TXMD Anderson Cancer Center· Houston, TX

Related Studies